JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB193415

Anti-HLAB 抗体

Anti-HLAB antibody

Be the first to review this product! Submit a review

|

(5 Publications)

Rabbit Polyclonal HLA B antibody. Suitable for WB, IHC-P, ICC/IF and reacts with Human samples. Cited in 5 publications. Immunogen corresponding to Recombinant Fragment Protein within Human HLA-B aa 1-350.

別名を表示する

HLAB, HLA-B, Human leukocyte antigen B

2 Images
Immunocytochemistry/ Immunofluorescence - Anti-HLAB antibody (AB193415)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-HLAB antibody (AB193415)

Immunocytochemistry/ Immunofluorescence analysis of HepG2 cells labeling HLAB with ab193415 at a dilution of 1/100.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-HLAB antibody (AB193415)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-HLAB antibody (AB193415)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human spleen tissue labeling HLAB with ab193415 at 1/100 dilution.

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

WB, IHC-P, ICC/IF

applications

免疫原

Recombinant Fragment Protein within Human HLA-B aa 1-350. The exact immunogen used to generate this antibody is proprietary information.

P01889

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>" } } }

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein G
精製に関する特記事項
>95%
バッファー組成
pH: 7.4 Preservative: 0.03% Proclin 300 Constituents: PBS, 50% Glycerol (glycerin, glycerine)
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed : 23209413, PubMed : 25808313, PubMed : 29531227, PubMed : 9620674). May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity (PubMed : 18991276, PubMed : 7743181). Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells (PubMed : 24600035, PubMed : 29531227, PubMed : 9620674). Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via constitutive proteasome and IFNG-induced immunoproteasome (PubMed : 23209413). Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9 (PubMed : 25808313, PubMed : 29531227).. Allele B*07 : 02 : Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and mainly a Leu anchor residue at the C-terminus (PubMed : 7743181). Presents a long peptide (APRGPHGGAASGL) derived from the cancer-testis antigen CTAG1A/NY-ESO-1, eliciting a polyclonal CD8-positive T cell response against tumor cells (PubMed : 29531227). Presents viral epitopes derived from HIV-1 gag-pol (TPQDLNTML) and Nef (RPQVPLRPM) (PubMed : 25808313). Presents an immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein (SPRWYFYYL) (PubMed : 32887977). Displays self-peptides including a peptide derived from the signal sequence of HLA-DPB1 (APRTVALTA) (PubMed : 7743181).. Allele B*08 : 01 : Presents to CD8-positive T cells viral epitopes derived from EBV/HHV-4 EBNA3 (QAKWRLQTL), eliciting cytotoxic T cell response.. Allele B*13 : 02 : Presents multiple HIV-1 epitopes derived from gag (RQANFLGKI, GQMREPRGSDI), nef (RQDILDLWI), gag-pol (RQYDQILIE, GQGQWTYQI) and rev (LQLPPLERL), all having in common a Gln residue at position 2 and mainly hydrophobic amino acids Leu, Ile or Val at the C-terminus. Associated with successful control of HIV-1 infection.. Allele B*18 : 01 : Preferentially presents octameric and nonameric peptides sharing a common motif, namely a Glu at position 2 and Phe or Tyr anchor residues at the C-terminus (PubMed : 14978097, PubMed : 18991276, PubMed : 23749632). Presents an EBV/HHV-4 epitope derived from BZLF1 (SELEIKRY) (PubMed : 23749632). May present to CD8-positive T cells an antigenic peptide derived from MAGEA3 (MEVDPIGHLY), triggering an anti-tumor immune response (PubMed : 12366779). May display a broad repertoire of self-peptides with a preference for peptides derived from RNA-binding proteins (PubMed : 14978097).. Allele B*27 : 05 : Presents to CD8-positive T cells immunodominant viral epitopes derived from HCV POLG (ARMILMTHF), HIV-1 gag (KRWIILGLNK), IAV NP (SRYWAIRTR), SARS-CoV-2 N/nucleoprotein (QRNAPRITF), EBV/HHV-4 EBNA4 (HRCQAIRKK) and EBV/HHV-4 EBNA6 (RRIYDLIEL), conferring longterm protection against viral infection (PubMed : 15113903, PubMed : 18385228, PubMed : 19139562, PubMed : 32887977, PubMed : 9620674). Can present self-peptides derived from cytosolic and nuclear proteins. All peptides carry an Arg at position 2 (PubMed : 1922338). The peptide-bound form interacts with NK cell inhibitory receptor KIR3DL1 and inhibits NK cell activation in a peptide-specific way, being particularly sensitive to the nature of the amino acid side chain at position 8 of the antigenic peptide (PubMed : 15657948, PubMed : 8879234). KIR3DL1 fails to recognize HLA-B*27 : 05 in complex with B2M and EBV/HHV-4 EBNA6 (RRIYDLIEL) peptide, which can lead to increased activation of NK cells during infection (PubMed : 15657948). May present an altered repertoire of peptides in the absence of TAP1-TAP2 and TAPBPL (PubMed : 9620674).. Allele B*40 : 01 : Presents immunodominant viral epitopes derived from EBV/HHV-4 LMP2 (IEDPPFNSL) and SARS-CoV-2 N/nucleoprotein (MEVTPSGTWL), triggering memory CD8-positive T cell response (PubMed : 18991276, PubMed : 32887977). Displays self-peptides sharing a signature motif, namely a Glu at position 2 and a Leu anchor residue at the C-terminus (PubMed : 18991276).. Allele B*41 : 01 : Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor residues at the C-terminus.. Allele B*44 : 02 : Presents immunodominant viral epitopes derived from EBV/HHV-4 EBNA4 (VEITPYKPTW) and EBNA6 (AEGGVGWRHW, EENLLDFVRF), triggering memory CD8-positive T cell response (PubMed : 18991276, PubMed : 9620674). Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Phe, Tyr or Trp anchor residues at the C-terminus (PubMed : 18991276).. Allele B*45 : 01 : Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor residues at the C-terminus.. Allele B*46 : 01 : Preferentially presents nonameric peptides sharing a signature motif, namely Ala and Leu at position 2 and Tyr, Phe, Leu, or Met anchor residues at the C-terminus. The peptide-bound form interacts with KIR2DL3 and inhibits NK cell cytotoxic response in a peptide-specific way.. Allele B*47 : 01 : Displays self-peptides sharing a signature motif, namely an Asp at position 2 and Leu or Met anchor residues at the C-terminus.. Allele B*49 : 01 : Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ile or Val anchor residues at the C-terminus.. Allele B*50 : 01 : Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor residues at the C-terminus.. Allele B*51 : 01 : Presents an octameric HIV-1 epitope derived from gag-pol (TAFTIPSI) to the public TRAV17/TRBV7-3 TCR clonotype, strongly suppressing HIV-1 replication.. Allele B*54 : 01 : Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Ala anchor residue at the C-terminus.. Allele B*55 : 01 : Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Ala anchor residue at the C-terminus.. Allele B*56 : 01 : Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Ala anchor residue at the C-terminus.. Allele B*57 : 01 : The peptide-bound form recognizes KIR3DL1 and inhibits NK cell cytotoxic response. Presents HIV gag peptides (immunodominant KAFSPEVIPMF and subdominant KALGPAATL epitopes) predominantly to CD8-positive T cell clones expressing a TRAV41-containing TCR, triggering HLA-B-restricted T cell responses.. Allele B*67 : 01 : Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Leu anchor residue at the C-terminus.
See full target information HLA-B

文献 (5)

Recent publications for all applications. Explore the full list and refine your search

Cell reports 43:113792 PubMed38363679

2024

The HIF transcription network exerts innate antiviral activity in neurons and limits brain inflammation.

Applications

Unspecified application

Species

Unspecified reactive species

Ensieh Farahani,Line S Reinert,Ryo Narita,Manutea C Serrero,Morten Kelder Skouboe,Demi van der Horst,Sonia Assil,Baocun Zhang,Marie B Iversen,Eugenio Gutierrez,Hossein Hazrati,Mogens Johannsen,David Olagnier,Reiner Kunze,Mark Denham,Trine H Mogensen,Michael Lappe,Søren R Paludan

Nature communications 15:752 PubMed38272918

2024

MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides.

Applications

Unspecified application

Species

Unspecified reactive species

Yun-Tsan Chang,Pacôme Prompsy,Susanne Kimeswenger,Yi-Chien Tsai,Desislava Ignatova,Olesya Pavlova,Christoph Iselin,Lars E French,Mitchell P Levesque,François Kuonen,Malgorzata Bobrowicz,Patrick M Brunner,Steve Pascolo,Wolfram Hoetzenecker,Emmanuella Guenova

Carcinogenesis 43:1059-1070 PubMed36070764

2022

LAMTOR1 degrades MHC-II via the endocytic in hepatocellular carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Bo Wu,Qian Wang,Bowen Li,Meixi Jiang

Frontiers in oncology 12:763480 PubMed36110943

2022

La protein regulates protein expression by binding with the mRNAs of target genes and participates the pathological process of ovarian cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Xuan Huang,Jialei Zhu,Yueyan Li,Yang Yu,Jing Tang

Cancer research 79:2684-2696 PubMed30773503

2019

Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma.

Applications

Unspecified application

Species

Unspecified reactive species

Joanna Poźniak,Jérémie Nsengimana,Jonathan P Laye,Sally J O'Shea,Joey Mark S Diaz,Alastair P Droop,Anastasia Filia,Mark Harland,John R Davies,Tracey Mell,Juliette A Randerson-Moor,Sathya Muralidhar,Sabrina A Hogan,Sandra Nicole Freiberger,Mitchell P Levesque,Graham P Cook,D Timothy Bishop,Julia Newton-Bishop
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com